Measurements: Cost per ulcer cured over a one-year study period.
INTRODUCTION
Empiric antisecretory therapy has been widely recommended as the initial management for patients presenting with presumed peptic ulcer disease, with endoscopic evaluation reserved for persistent or recurrent symptoms [1] . However, the association between aTo whom all correspondence should be addressed: A. Mark Fendrick Helicobacter pylori and peptic ulcer disease compels rethinking of the management of this common clinical condition [2] [3] . While elimination of the organism slightly improves ulcer healing rates, the principal benefit is the dramatic reduction in ulcer recurrence rates in those patients in whom the infection has been successfully eradicated [4] [5] . In order to minimize inappropriate use of antibiotic therapy, guidelines such as those of an NIH Consensus Panel recommend a strategy that requires the objective documentation of an active ulcer and H. pylori infection prior to prescription of antibiotic treatment [6] .
Such a recommendation makes two assumptions. First, that diagnostic confirmation of both ulcer disease and H. pylori infection is the optimal strategy after careful consideration of benefits, risks and costs of available alternatives. Second, that community physicians, who are accustomed to using initial empiric therapy in patients with ulcer-like symptoms, will find this guideline instructive in their clinical practice. Accordingly, the objective of our study was to use decision analytic techniques to assess the impact of a non-invasive approach to patients presenting with symptoms suggestive of peptic ulcer disease.
MATERIALS AND METHODS

Decision analytic model
The details of the decision analytic model used in this study have been published previously elsewhere [7] . Using a decision analysis software program, Decision Maker 7.0 (Pratt Medical Group, Boston, Massachusetts), a simulation was constructed to predict the natural history of peptic ulcer disease, its interaction with H. pylori infection and the effects of various diagnostic and therapeutic medical interventions. The analysis started with a cohort of 1000 hypothetical patients presenting to a physician with symptoms suggestive of peptic ulcer disease who were not concurrently taking NSAIDSd. On [8] . Although antibody levels fall after eradication of the organism, they remain detectable in the serum in many instances. The persistence of H. pylori antibodies after eradication considerably diminishes the value of qualitative serology in assessing whether infection has been cured, in that a positive test can indicate either past or ongoing infection. Thus, in the simulation, a qualitative serologic test was used only in those patients who had not previously received H. pylori eradication therapy.
Once eradication therapy was prescribed, either biopsy for H. pylori or a urea breath test was used to confirm cure or establish ongoing H. pylori infection. If endoscopy and biopsy were not to be performed for a specific symptomatic encounter, a urea breath test was undertaken to evaluate the effectiveness in eradicating H. pylori. Individuals who failed to clear H. pylori after three courses of antibiotic therapy were assumed to be infected for the remainder of the study period. Once cleared of H. pylori, infection was assumed not to recur [9] .
Successful eradication of H. pylori in patients with ulcers associated with nonsteroidal anti-inflammatory medications or diagnoses other than active ulcer disease (e.g., gastritis) was assumed not to offer any benefit in terms of reducing symptom severity or preventing future ulcer development. Active ulcer disease Ulcer status determined the likelihood of symptomatic relief from therapy and, thus, determined the need for future physician visits and related medical interventions. Endoscopy was assumed to be a perfect test to diagnose ulcer disease and was presumed to have no associated adverse events. Ulcer recurrence, not associated with NSAID use, was related to H. pylori status and concurrent use of antisecretory therapy [5, 10] . Spontaneous ulcer development was assumed not to occur in patients whose initial symptoms were secondary to non-ulcer causes. Ulcers that failed to heal completely after three courses of antisecretory therapy required maintenance antisecretory therapy for the duration of the study period.
DATA SOURCES Clinical Probabilities
A Medline search was conducted for English language articles to provide pertinent clinical data for the simulation model. Bibliographies of accepted articles were reviewed and a search of current issues of the peer-reviewed, general medicine, infectious disease and gastroenterology literature was also undertaken to identify additional reports not included in the computerized database. In instances of data unavailability or uncertainty, unpublished data presented at the National Institutes of Health Consensus Development Meeting were used [6] . Clinical input probabilities and ranges used in the simulation are shown in Table 1 .
Multiple antibiotic and antisecretory regimens of varying efficacy, cost, and compliance were evaluated. The relatively small differences in ulcer healing and H. pylori eradication rates among available regimens were investigated using sensitivity analysis. Compliance and outcomes related to specific medication use, including antibiotic-related adverse events, were incorporated into these analyses. Sensitivity analysis Examination of clinical and cost inputs over broad ranges revealed that the cost-effectiveness advantage of non-invasive strategy (Strategy 2) relative to immediate endoscopy (Strategy 1) was sensitive to only two variables: 1) cost of endoscopy and 2) probability of recurrent symptoms in non-invasively treated patients in whom ulcer disease was not the underlying cause of their symptoms.
As the cost of endoscopy fell, the cost per patient treated of strategies using immediate endoscopy approached that of the non-invasive strategies (Figure 3 ). Endoscopy costs, inclusive of payments for professional fees and suite charges, must fall below $500 for an equivalent cost-effectiveness ratio to result. The cost-effectiveness advantage of non-invasive management was unchanged if biopsy were replaced by a less expensive CLO test. The other input variable found to be important in establishing an advantage for the non-invasive strategies was the probability of recurrent symptoms in patients without ulcer disease. Individuals without ulcer disease with recurrent symptoms after a course of empiric therapy incurred the cost of invasive diagnostic testing (mandatory for recurrent symptoms in all non-invasively treated patients) in addition to the cost of initial therapy. Therefore, as the probability of recurrent symptoms rose in this population, the potential savings of initial non-invasive management diminished as the use of endoscopy increased. As the annual recurrent symptom rate approached 80 percent, the cost per patient treated of the non-invasive strategy approached that of the immediate endoscopy (Figure 4) . Sensitivity analysis which simultaneously varied the cost of endoscopy and the probability of recurrent symptoms in non-ulcer patients was performed. This analysis revealed that the choice of immediate endoscopy and biopsy (Strategy 1) versus test-and-treat (Strategy 2) can be determined at different values of these clinical and economic inputs ( Figure 5) . DISCUSSION In 1985, an American College of Physicians Position Paper supported empiric antisecretory therapy as the initial management for patients presenting with presumed peptic ulcer disease, recommending endoscopy only in those individuals who failed an appropriate course of therapy [1] . The realization that acid suppression must be accompanied by H. pylori eradication to prevent ulcer recurrence, necessitates reevaluating this existing treatment algorithm.
The NIH Consensus Panel Statement implicitly endorsed a strategy to document the presence of both an ulcer and H. pylori infection prior to prescribing eradication therapy [6] . The recommendation requiring confirmation of both diagnoses has raised considerable uncertainty among clinicians who have widely accepted an empiric first-line management of patients with presumed peptic ulcer disease. Compliance with the NIH Consensus Panel recommendations would require increased invasive diagnostic testing prior to treatment, necessitating increased health system and patient-related costs to achieve perfect diagnostic information.
Our cost-effectiveness analysis supports the continued use of a non-invasive treatment strategy incorporating a serologic test for H. pylori infection at the first symptomatic episode, changing somewhat the strategy of initial empiric H2 blocker therapy commonly used in clinical practice. We recommend a single course of empiric therapy guided by a non-invasive serologic test for H. pylori. In our simulation, endoscopy was performed on all patients who remained symptomatic or in whom symptoms recurred.
Although the cost-effectiveness ratios included antibiotic-related adverse events, the analysis did not include the non-drug costs of over-prescribing antibiotics which, in theory, increase the likelihood of H. pylori resistance [11] . The issue of bacterial resistance is a real one when discussing broad use of antibiotics, especially when an important percentage of patients prescribed these agents may not receive clinical benefit, in that ulcer disease was not the cause of the symptoms. At present, data are being collected to allow quantification of antibiotic resistance. This calculation is complicated by the fact that all of the antibiotic agents currently recommended (but not FDA approved) for treatment of H. pylori are prescribed for other clinical indications.
Promotion of antibiotic resistance is not frequently considered in the individual patient-physician episode of care, but is an important societal issue. Nonetheless, the potential to maintain effective treatments in the future is of considerable importance. Interestingly, antibiotic resistance to H. pylori may be viewed differently by clinicians, in that when compared to other pathogens (e.g., S. aureus) H. pylori has a relatively low level of infectiousness, and resultant infection does not cause significant morbidity in a majority of cases.
The cost-effectiveness advantage for the non-invasive strategies over a strategy of immediate endoscopy was sensitive to two inputs: the cost of endoscopy and the probability of recurrent symptoms leading to eventual endoscopy. Lower payments for endoscopy, such as those found in competitive, managed care markets or delivery systems outside the United States, may lead to a different strategy choice. Independent of endoscopy cost, as the likelihood of eventual endoscopy increased, the savings achieved by initially avoiding this diagnostic test was lost. A recent prospective trial from Denmark comparing empiric H2 blocker therapy and immediate endoscopy reported that 65 percent of empirically treated patients with dyspepsia eventually underwent endoscopy, although no attempts at H. pylori eradication were attempted [12] . At this rate of recurrent symptoms, the cost-effectiveness advantage of the initial non-invasive strategy was minimal (Figure 4) . CONCLUSION Endoscopy, though costly, precisely guides diagnosis and treatment and, thus, potentially reduces the number of patients treated unnecessarily with antibiotics. However, our cost-effectiveness analysis supports the continued practice of initial non-invasive management of patients with symptoms suggestive of peptic ulcer disease, but achieves the benefits of H. pylori eradication through the use of serologic testing to guide antibiotic use.
